45,266 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 45,266 shares of the biotechnology company's stock, valued at approximately $16,224,000. Erste Asset Management GmbH owned approximately 0.10% of United Therapeutics at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. LSV Asset Management increased its stake in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock valued at $307,837,000 after purchasing an additional 436,851 shares in the last quarter. FMR LLC increased its position in United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after buying an additional 314,004 shares in the last quarter. Assetmark Inc. increased its position in United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock valued at $150,492,000 after buying an additional 152,249 shares in the last quarter. Pacer Advisors Inc. raised its stake in United Therapeutics by 19.6% during the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock valued at $178,972,000 after buying an additional 92,240 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in United Therapeutics by 49.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company's stock worth $88,089,000 after acquiring an additional 91,597 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares of the company's stock, valued at $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 224 shares of the firm's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the sale, the director now owns 5,783 shares in the company, valued at $2,384,215.24. The trade was a 3.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 127,227 shares of company stock valued at $47,398,820 in the last 90 days. Company insiders own 11.90% of the company's stock.

United Therapeutics Stock Down 0.1 %

Shares of United Therapeutics stock traded down $0.37 during trading hours on Monday, reaching $370.12. 315,271 shares of the stock traded hands, compared to its average volume of 456,115. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The firm has a market capitalization of $16.53 billion, a price-to-earnings ratio of 16.27, a P/E/G ratio of 1.08 and a beta of 0.56. The company has a 50 day moving average price of $367.77 and a 200 day moving average price of $336.09.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same period in the previous year, the business posted $5.38 earnings per share. The firm's quarterly revenue was up 22.9% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on UTHR shares. Argus lifted their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group increased their target price on United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.